# Official Journal C 130/27 M

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 130 |
| | |
| English edition | Information and Notices | Volume 4827 May 2005 |

ISSN 1725-2423

Official Journal

of the European Union

C 130

English edition

Information and Notices

Volume 4827 May 2005

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Commission |
| 2005/C 130/1 | Euro exchange rates | 1 |
| 2005/C 130/2 | Final report of the Hearing Officer in Case COMP/37.214 — DFB Joint Selling of Media Rights (pursuant to Article 15 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21) (
  1
  ) | 2 |
| 2005/C 130/3 | Opinion of the Advisory Committee on restrictive practices and dominant positions given at its 386th meeting on 6 December 2004 concerning a preliminary draft decision in Case COMP/A.37.214 — DFB (
  1
  ) | 4 |
| 2005/C 130/4 | Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) | 5 |
| 2005/C 130/5 | Notice of the impending expiry of certain anti-dumping measures (This text replaces the one published in Official Journal C 94 of 19 April 2005, p. 2.) | 8 |
| 2005/C 130/6 | Non-opposition to a notified concentration (Case COMP/M.2483 — Group Canal+/RTL/GJCD/JV) (
  1
  ) | 9 |

Notice No

Contents

page

I   Information

Commission

2005/C 130/1

Euro exchange rates

1

2005/C 130/2

Final report of the Hearing Officer in Case COMP/37.214 — DFB Joint Selling of Media Rights (pursuant to Article 15 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21) (
  1
  )

1

2

2005/C 130/3

Opinion of the Advisory Committee on restrictive practices and dominant positions given at its 386th meeting on 6 December 2004 concerning a preliminary draft decision in Case COMP/A.37.214 — DFB (
  1
  )

1

4

2005/C 130/4

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

5

2005/C 130/5

Notice of the impending expiry of certain anti-dumping measures (This text replaces the one published in Official Journal C 94 of 19 April 2005, p. 2.)

(This text replaces the one published in Official Journal C 94 of 19 April 2005, p. 2.)

8

2005/C 130/6

Non-opposition to a notified concentration (Case COMP/M.2483 — Group Canal+/RTL/GJCD/JV) (
  1
  )

1

9

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

I Information

Commission

| 27.5.2005 | EN | Official Journal of the European Union | C 130/1 |
| --- | --- | --- | --- |

27.5.2005

EN

Official Journal of the European Union

C 130/1

---

Euro exchange rates (1)

26 May 2005

(2005/C 130/01)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2523 |
| JPY | Japanese yen | 135,58 |
| DKK | Danish krone | 7,4438 |
| GBP | Pound sterling | 0,6874 |
| SEK | Swedish krona | 9,2 |
| CHF | Swiss franc | 1,5472 |
| ISK | Iceland króna | 81,02 |
| NOK | Norwegian krone | 8,009 |
| BGN | Bulgarian lev | 1,9559 |
| CYP | Cyprus pound | 0,5764 |
| CZK | Czech koruna | 30,495 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 254,26 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6959 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 4,1775 |
| ROL | Romanian leu | 36 144 |
| SIT | Slovenian tolar | 239,52 |
| SKK | Slovak koruna | 39,21 |
| TRY | Turkish lira | 1,7358 |
| AUD | Australian dollar | 1,6473 |
| CAD | Canadian dollar | 1,5886 |
| HKD | Hong Kong dollar | 9,7439 |
| NZD | New Zealand dollar | 1,7595 |
| SGD | Singapore dollar | 2,0801 |
| KRW | South Korean won | 1 254,55 |
| ZAR | South African rand | 8,2949 |
| CNY | Chinese yuan renminbi | 10,3647 |
| HRK | Croatian kuna | 7,318 |
| IDR | Indonesian rupiah | 11 884,33 |
| MYR | Malaysian ringgit | 4,7586 |
| PHP | Philippine peso | 68,282 |
| RUB | Russian rouble | 35,18 |
| THB | Thai baht | 50,599 |

Currency

Exchange rate

USD

US dollar

1,2523

JPY

Japanese yen

135,58

DKK

Danish krone

7,4438

GBP

Pound sterling

0,6874

SEK

Swedish krona

9,2

CHF

Swiss franc

1,5472

ISK

Iceland króna

81,02

NOK

Norwegian krone

8,009

BGN

Bulgarian lev

1,9559

CYP

Cyprus pound

0,5764

CZK

Czech koruna

30,495

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

254,26

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6959

MTL

Maltese lira

0,4293

PLN

Polish zloty

4,1775

ROL

Romanian leu

36 144

SIT

Slovenian tolar

239,52

SKK

Slovak koruna

39,21

TRY

Turkish lira

1,7358

AUD

Australian dollar

1,6473

CAD

Canadian dollar

1,5886

HKD

Hong Kong dollar

9,7439

NZD

New Zealand dollar

1,7595

SGD

Singapore dollar

2,0801

KRW

South Korean won

1 254,55

ZAR

South African rand

8,2949

CNY

Chinese yuan renminbi

10,3647

HRK

Croatian kuna

7,318

IDR

Indonesian rupiah

11 884,33

MYR

Malaysian ringgit

4,7586

PHP

Philippine peso

68,282

RUB

Russian rouble

35,18

THB

Thai baht

50,599

---

(1)

Source: reference exchange rate published by the ECB.

---

| 27.5.2005 | EN | Official Journal of the European Union | C 130/2 |
| --- | --- | --- | --- |

27.5.2005

EN

Official Journal of the European Union

C 130/2

---

Final report of the Hearing Officer in Case COMP/37.214 — DFB Joint Selling of Media Rights

(pursuant to Article 15 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21)

(2005/C 130/02)

(Text with EEA relevance)

The decision concerns the central marketing of the media exploitation rights in respect of matches in the first and second national football divisions for men (Bundesliga and 2. Bundesliga) by the Liga-Fußballverband e.V. (‘League Association’) in Germany. The League association is a registered association and ordinary member of the Deutscher Fußballbund (‘DFB’ — German Football Association).

By letter of 25 August 1998, the DFB, in accordance with Articles 2 and 4 of Regulation No 17/62, applied for negative clearance or, failing this, an individual exemption under Article 81(3) of the Treaty in respect of the central marketing of television and radio broadcasting rights and any other technical forms of exploitation for matches in the first and second national football divisions for men. The League Association, which was founded in 2001 and which took over the task of marketing from the DFB, adopted the DFB's amended notification as its own on 19 February 2003.

On 9 January 1999 the Commission, in a notice published in the Official Journal of the European Communities, invited third parties to submit their observations. (1) By decision of 22 October 2003, it initiated proceedings under Article 9(3) of Regulation No 17. On 30 October 2003 it announced its intention of giving a positive assessment of the amended joint marketing arrangements in a notice published in the Official Journal of the European Union
   (2) and subsequently received observations from interested third parties.

With the entry into force of Council Regulation (EC) No 1/2003 on 1 May 2004, the League Association's former application for negative clearance or individual exemption lapsed in accordance with Article 34(1) of Regulation (EC) No 1/2003.

However, in accordance with Article 34(2) of Regulation (EC) No 1/2003, the initiation of proceedings under Article 9(3) of Regulation No 17 which corresponds to that under Article 2(1) of Implementing Regulation (EC) No 773/2004, continued to have effect.

Accordingly, with effect from 1 May 2004, the Commission, acting on its own initiative, continued with the proceedings with a view to adopting a decision under Chapter III of Regulation (EC) No 1/2003.

On 18 June 2004 the Commission issued a preliminary assessment in accordance with Article 9(1) of Regulation (EC) No 1/2003 that was addressed to the League Association and made available to the DFB.

By letter of 6 August 2004, the League Association submitted amended undertakings in respect of the central marketing arrangements as commitments within the meaning of Article 9(1) of Regulation (EC) No 1/2003.

On 14 September 2004 the Commission, in a notice published pursuant to Article 27(4) of Regulation (EC) No 1/2003 in the Official Journal of the European Union, invited interested third parties to submit observations on the proposed commitments within one month of the publication of the notice. These observations were transmitted to the League Association.

In light of the commitments offered by the League Association, the Commission considers that there are no longer grounds for action by the Commission and, without prejudice to Article 9(2) of Regulation (EC) No 1/2003, the proceedings in the present case shall be brought to an end.

No queries were raised before the Hearing Officer by the League Association or other companies as to the market test. No requests for additional information were made. The League Association has informed the Commission that the information necessary to assess the case was at its disposal.

In the light of the above, the case does not call for any particular comments as regards the right to be heard.

Brussels, 7 December 2004.

Serge DURANDE

---

(1)  OJ C 6, 9.1.1999, p. 10.

1

(2)  OJ C 261, 30.10.2003, p. 13.

2

---

| 27.5.2005 | EN | Official Journal of the European Union | C 130/4 |
| --- | --- | --- | --- |

27.5.2005

EN

Official Journal of the European Union

C 130/4

---

Opinion of the Advisory Committee on restrictive practices and dominant positions given at its 386th meeting on 6 December 2004 concerning a preliminary draft decision in Case COMP/A.37.214 — DFB

(2005/C 130/03)

(Text with EEA relevance)

| 1. | The majority of the Advisory Committee agrees that the joint selling of the media rights by the German Bundesliga raises competition concerns under Article 81(1) and the proceedings in this case can be concluded by means of a decision pursuant to Article 9 of Council Regulation (EC) No 1/2003. A minority voted against. A minority abstains. |
| --- | --- |

1.

The majority of the Advisory Committee agrees that the joint selling of the media rights by the German Bundesliga raises competition concerns under Article 81(1) and the proceedings in this case can be concluded by means of a decision pursuant to Article 9 of Council Regulation (EC) No 1/2003. A minority voted against. A minority abstains.

| 2. | The majority of the Advisory Committee agrees with the European Commission that the league Association's commitments introduce competition in the marketing of Bundesliga and 2. Bundesliga rights between the league and the clubs and allow for new in particular club branded products, reduce the scope and duration of future marketing deals and provide a transparent and non-discriminatory procedure, and improve accessibility of content for TV, Radio and the new media operators. A minority voted against. A minority abstains. |
| --- | --- |

2.

The majority of the Advisory Committee agrees with the European Commission that the league Association's commitments introduce competition in the marketing of Bundesliga and 2. Bundesliga rights between the league and the clubs and allow for new in particular club branded products, reduce the scope and duration of future marketing deals and provide a transparent and non-discriminatory procedure, and improve accessibility of content for TV, Radio and the new media operators. A minority voted against. A minority abstains.

| 3. | The majority of the Advisory Committee agrees with the European Commission that — in light of the commitments offered by the Undertaking — there are no longer grounds for action by the Commission, without prejudice to Article 9(2) of Council Regulation (EC) No 1/2003. A minority voted against. A minority abstains. |
| --- | --- |

3.

The majority of the Advisory Committee agrees with the European Commission that — in light of the commitments offered by the Undertaking — there are no longer grounds for action by the Commission, without prejudice to Article 9(2) of Council Regulation (EC) No 1/2003. A minority voted against. A minority abstains.

| 4. | The majority of the Advisory Committee agrees with the European Commission that these commitments shall be binding on the League Association until 30 June 2009. A minority voted against. A minority abstains. |
| --- | --- |

4.

The majority of the Advisory Committee agrees with the European Commission that these commitments shall be binding on the League Association until 30 June 2009. A minority voted against. A minority abstains.

| 5. | The Advisory Committee recommends the publication of its opinion in the Official Journal of the European Union. |
| --- | --- |

5.

The Advisory Committee recommends the publication of its opinion in the Official Journal of the European Union.

| 6. | The Advisory Committee asks the Commission to take into account all the other points raised during the discussion. |
| --- | --- |

6.

The Advisory Committee asks the Commission to take into account all the other points raised during the discussion.

---

| 27.5.2005 | EN | Official Journal of the European Union | C 130/5 |
| --- | --- | --- | --- |

27.5.2005

EN

Official Journal of the European Union

C 130/5

---

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) (1)

(2005/C 130/04)

—   Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 20.4.2005 | Velcade | Janssen-Cilag International NV, Turnhoutseweg, 30 — B-2340 Beerse | EU/1/04/274/001 | 22.4.2005 |
| 20.4.2005 | Viramune | Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein | EU/1/97/055/001-002 | 22.4.2005 |
| 20.4.2005 | Paxene | Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom | EU/1/99/113/001-004 | 22.4.2005 |
| 25.4.2005 | Zeffix | Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom | EU/1/99/114/001-003 | 27.4.2005 |
| 25.4.2005 | HBVAXPRO | Sanofi Pasteur MSD, SNC, 8, rue Jonas Salk, F-69007 Lyon | EU/1/01/183/001-019 | 27.4.2005 |
| 25.4.2005 | Humira | Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom | EU/1/03/256/001-006 | 27.4.2005 |
| 25.4.2005 | GONAL f | Serono Europe Limited, 56, Marsh Wall, London E14 9TP, United Kingdom | EU/1/95/001/001-035 | 27.4.2005 |
| 25.4.2005 | Trudexa | Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom | EU/1/03/257/001-006 | 27.4.2005 |
| 27.4.2005 | Viagra | Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom | EU/1/98/077/001-012 | 29.4.2005 |
| 27.4.2005 | Keppra | UCB SA, Allée de la recherche, 60, B-1070 Bruxelles
  Researchdreef, 60, B-1070 Brussel | EU/1/00/146/001-027 | 29.4.2005 |
| 27.4.2005 | Lantus | Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main | EU/1/00/134/012 | 29.4.2005 |
| 27.4.2005 | Optisulin | Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main | EU/1/00/133/008 | 29.4.2005 |
| 27.4.2005 | Forsteo | Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland | EU/1/03/247/001-002 | 29.4.2005 |
| 27.4.2005 | Neupopeg | Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano | EU/1/02/228/001-002 | 29.4.2005 |
| 27.4.2005 | Cellcept | Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom | EU/1/96/005/001-006 | 29.4.2005 |
| 27.4.2005 | Carbaglu | Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense | EU/1/02/246/001-003 | 29.4.2005 |
| 28.4.2005 | Herceptin | Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom | EU/1/00/145/001 | 3.5.2005 |
| 28.4.2005 | Emend | Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/03/262/001-006 | 3.5.2005 |
| 28.4.2005 | Emend | Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/03/262/001-006 | 3.5.2005 |
| 28.4.2005 | Enbrel | Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/99/126/006-011 | 3.5.2005 |
| 28.4.2005 | Rapamune | Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom | EU/1/01/171/001-012 | 3.5.2005 |
| 29.4.2005 | Neulasta | Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland | EU/1/02/227/001-002 | 3.5.2005 |
| 10.5.2005 | Lyrica | Pfizer Ltd; Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom | EU/1/04/279/001-025 | 13.5.2005 |
| 10.5.2005 | Cancidas | Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom | EU/1/01/196/001-003 | 13.5.2005 |
| 13.5.2005 | Apidra | Aventis Pharma Deutschland GmbH, Brueningstraße 50, D-65926 Frankfurt am Main | EU/1/04/285/001-028 | 18.5.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

20.4.2005

Velcade

Janssen-Cilag International NV, Turnhoutseweg, 30 — B-2340 Beerse

EU/1/04/274/001

22.4.2005

20.4.2005

Viramune

Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein

EU/1/97/055/001-002

22.4.2005

20.4.2005

Paxene

Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom

EU/1/99/113/001-004

22.4.2005

25.4.2005

Zeffix

Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

EU/1/99/114/001-003

27.4.2005

25.4.2005

HBVAXPRO

Sanofi Pasteur MSD, SNC, 8, rue Jonas Salk, F-69007 Lyon

EU/1/01/183/001-019

27.4.2005

25.4.2005

Humira

Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom

EU/1/03/256/001-006

27.4.2005

25.4.2005

GONAL f

Serono Europe Limited, 56, Marsh Wall, London E14 9TP, United Kingdom

EU/1/95/001/001-035

27.4.2005

25.4.2005

Trudexa

Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom

EU/1/03/257/001-006

27.4.2005

27.4.2005

Viagra

Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom

EU/1/98/077/001-012

29.4.2005

27.4.2005

Keppra

UCB SA, Allée de la recherche, 60, B-1070 Bruxelles

Researchdreef, 60, B-1070 Brussel

EU/1/00/146/001-027

29.4.2005

27.4.2005

Lantus

Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

EU/1/00/134/012

29.4.2005

27.4.2005

Optisulin

Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main

EU/1/00/133/008

29.4.2005

27.4.2005

Forsteo

Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland

EU/1/03/247/001-002

29.4.2005

27.4.2005

Neupopeg

Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano

EU/1/02/228/001-002

29.4.2005

27.4.2005

Cellcept

Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

EU/1/96/005/001-006

29.4.2005

27.4.2005

Carbaglu

Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense

EU/1/02/246/001-003

29.4.2005

28.4.2005

Herceptin

Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

EU/1/00/145/001

3.5.2005

28.4.2005

Emend

Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/03/262/001-006

3.5.2005

28.4.2005

Emend

Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/03/262/001-006

3.5.2005

28.4.2005

Enbrel

Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/99/126/006-011

3.5.2005

28.4.2005

Rapamune

Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom

EU/1/01/171/001-012

3.5.2005

29.4.2005

Neulasta

Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland

EU/1/02/227/001-002

3.5.2005

10.5.2005

Lyrica

Pfizer Ltd; Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

EU/1/04/279/001-025

13.5.2005

10.5.2005

Cancidas

Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

EU/1/01/196/001-003

13.5.2005

13.5.2005

Apidra

Aventis Pharma Deutschland GmbH, Brueningstraße 50, D-65926 Frankfurt am Main

EU/1/04/285/001-028

18.5.2005

—   Withdrawal of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 25.4.2005 | Infanrix Hep B | GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart | EU/1/97/048/001-014 | 27.4.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

25.4.2005

Infanrix Hep B

GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart

EU/1/97/048/001-014

27.4.2005

—   Modification of a marketing authorisation (Article 34 of Council Regulation (EEC) No 2309/93): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorisation | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 18.4.2005 | Bayovac CSF E2 | Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom
  Bayer AG, Geschäftsbereich Tiergesundheit, D-51368 Leverkusen | EU/2/00/025/001-004 | 20.4.2005 |
| 21.4.2005 | Eurifel FeLV | Merial, 29 Avenue Tony Garnier, F-69007 Lyon | EU/2/00/019/001-003 | 27.4.2005 |
| 27.4.2005 | Ibraxion | Merial, 29 avenue Tony Garnier, F-69007 Lyon | EU/2/99/017/001-006 | 29.4.2005 |
| 27.4.2005 | Metacam | Boehringer Ingelheim Vetmedica GmbH, D-55216 Ingelheim am Rhein | EU/2/97/004/001
  EU/2/97/004/003-010 | 29.4.2005 |

Date of the decision

Name of the medicinal product

Holder of the marketing authorisation

Number of the entry in the Community Register

Date of notification

18.4.2005

Bayovac CSF E2

Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom

Bayer AG, Geschäftsbereich Tiergesundheit, D-51368 Leverkusen

EU/2/00/025/001-004

20.4.2005

21.4.2005

Eurifel FeLV

Merial, 29 Avenue Tony Garnier, F-69007 Lyon

EU/2/00/019/001-003

27.4.2005

27.4.2005

Ibraxion

Merial, 29 avenue Tony Garnier, F-69007 Lyon

EU/2/99/017/001-006

29.4.2005

27.4.2005

Metacam

Boehringer Ingelheim Vetmedica GmbH, D-55216 Ingelheim am Rhein

EU/2/97/004/001

EU/2/97/004/003-010

29.4.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| The European Medicines Agency |
| --- |
| 7, Westferry Circus, Canary Wharf |
| London E14 4HB |
| United Kingdom |

The European Medicines Agency

7, Westferry Circus, Canary Wharf

London E14 4HB

United Kingdom

---

(1)  OJ L 214 of 24.8.1993, p. 1.

---

| 27.5.2005 | EN | Official Journal of the European Union | C 130/8 |
| --- | --- | --- | --- |

27.5.2005

EN

Official Journal of the European Union

C 130/8

---

Notice of the impending expiry of certain anti-dumping measures

(This text replaces the one published in Official Journal C 94 of 19 April 2005, p. 2.)

(2005/C 130/05)

| 1. | As provided for in Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995 (1) on protection against dumped imports from countries not members of the European Community, the Commission gives notice that, unless a review is initiated in accordance with the following procedure, the anti-dumping measures mentioned below will expire on the date mentioned in the table below. |
| --- | --- |

1.

As provided for in Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995 (1) on protection against dumped imports from countries not members of the European Community, the Commission gives notice that, unless a review is initiated in accordance with the following procedure, the anti-dumping measures mentioned below will expire on the date mentioned in the table below.

2.   Procedure

Community producers may lodge a written request for a review. This request must contain sufficient evidence that the expiry of the measures would be likely to result in a continuation or recurrence of dumping and injury.

Should the Commission decide to review the measures concerned, importers, exporters, representatives of the exporting country and Community producers will then be provided with the opportunity to amplify, rebut or comment on the matters set out in the review request.

3.   Time limit

Community producers may submit a written request for a review on the above basis, to reach the European Commission, Directorate-General for Trade (Division B-1), J-79 5/16, B-1049 Brussels (2) at any time from the date of the publication of the present notice but no later than three months before the date mentioned in the table below.

| 4. | This notice is published in accordance with Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995. |
| --- | --- |

4.

This notice is published in accordance with Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995.

| Product | Country(ies) of origin or exportation | Measures | Reference | Date of expiry |
| --- | --- | --- | --- | --- |
| Coke of coal in pieces with a diameter of more than 80 mm | People's Republic of China | Anti-dumping duty | Commission Decision No 2730/2000/ECSC (OJ L 316, 15.12.2000, p. 30) (suspended by Council Regulation (EC) No 2117/2004 — OJ L 367, 14.12.2004, p. 3) as last amended by Council Regulation (EC) No 997/2004 (OJ L 183, 20.5.2004, p. 1) | 16.12.2005 |
| Polyester staple fibres | India | Anti-dumping duty | Council Regulation (EC) No 2852/2000 (OJ L 332, 28.12.2000, p. 17) | 29.12.2005 |
| India | Undertaking | Commission Decision No 2000/818/EC (OJ L 332, 28.12.2000, p. 116) | 29.12.2005 |

Product

Country(ies) of origin or exportation

Measures

Reference

Date of expiry

Coke of coal in pieces with a diameter of more than 80 mm

People's Republic of China

Anti-dumping duty

Commission Decision No 2730/2000/ECSC (OJ L 316, 15.12.2000, p. 30) (suspended by Council Regulation (EC) No 2117/2004 — OJ L 367, 14.12.2004, p. 3) as last amended by Council Regulation (EC) No 997/2004 (OJ L 183, 20.5.2004, p. 1)

16.12.2005

Polyester staple fibres

India

Anti-dumping duty

Council Regulation (EC) No 2852/2000 (OJ L 332, 28.12.2000, p. 17)

29.12.2005

India

Undertaking

Commission Decision No 2000/818/EC (OJ L 332, 28.12.2000, p. 116)

29.12.2005

---

(1)  OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Council Regulation (EC) No 461/2004 (OJ L 77, 13.3.2004, p. 12).

(2)  Telefax : (32-2) 295 65 05.

---

| 27.5.2005 | EN | Official Journal of the European Union | C 130/9 |
| --- | --- | --- | --- |

27.5.2005

EN

Official Journal of the European Union

C 130/9

---

Non-opposition to a notified concentration

(Case COMP/M.2483 — Group Canal+/RTL/GJCD/JV)

(2005/C 130/06)

(Text with EEA relevance)

On 13 November 2001, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EEC) No 4064/89. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition web site (http://europa.eu.int/comm/competition/mergers/cases/). This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition web site (http://europa.eu.int/comm/competition/mergers/cases/). This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32001M2483. EUR-Lex is the on-line access to European law. (http://europa.eu.int/eur-lex/lex) |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32001M2483. EUR-Lex is the on-line access to European law. (http://europa.eu.int/eur-lex/lex)

---